Clarient, Inc., a GE Healthcare Company, Introduces First Lab Developed Test to Assess Multiple Proteins at Single-Cell Level

Published: Jul 10, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LISO VIEJO, Calif.--(BUSINESS WIRE)--GE Healthcare today announced the introduction by Clarient Diagnostic Services, a GE Healthcare Company, of the first lab developed test using MultiOmyx™, a ground-breaking new pathology platform which uses proprietary methodology to assess multiple proteins from a single tissue section at a single-cell level. This test, now available, offers an aid to a pathologist’s diagnosis of CD30-positive lymphoma cases with difficult morphology or otherwise insufficient tissue to adequately evaluate the case.

Help employers find you! Check out all the jobs and post your resume.

Back to news